In order to confirm the requirement of CD8+ T cells and NK cells for responsiveness to N-803 + αPD-L1 therapy, we also performed CD8+ T cell and NK cell depletions in MC38-CEA tumor-bearing mice. This evidence concerns the gene CD8A and neoplasm.